Better Buy: Cara Therapeutics vs. Sangamo Therapeutics

You can't lump all clinical-stage biotechs together. Take Cara Therapeutics (NASDAQ: CARA) and Sangamo Therapeutics (NASDAQ: SGMO), for example. The two biotechs are about as different as night and day. One thing that both Cara and Sangamo have in common, though, are promising pipeline candidates. 

Investors have placed a greater value on Sangamo's pipeline based on the company's higher market cap. But which of these biotech stocks is the better pick for long-term investors? Here's how Cara and Sangamo stack up against each other.

Image source: Getty Images.

Continue reading

Source Fool.com